CGG has provided a full year 2020 & Q4 financial update. Q4 2020 Segment revenue expected at $282 million. Segment backlog as of January 1, 2021 at $421 million. Sells Shearwater shares to Rasmussengruppen.
Bahamas Petroleum Company, the Caribbean and Atlantic margin focused oil and gas company, with production, appraisal, development and exploration assets across the region, has provided an update on its funding.
(2)
Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers
Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim s position in the cancer vaccine and T-cell engager spaces
Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio s EDAPT platform and Dark Antigen discovery work and supports ongoing cell therapy based therapeutic approach
Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio s Dark Antigen discovery platform. This new collaboration combines Boehringer Ingelheim s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio s expertise in cancer antigen identification. The aim is to provide poten
I have an overseas driving licence from a non-approved country. Hence, I understood that I have to take the knowledge test and the practical driving test or go with the logbook system. My question
(1)
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium - 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed. CanProbe s NET clinical program has helped many patients in Ontario who previously had no other options for treatment, says Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. We are excited to extend access to this treatment by leveraging CanProbe s intellectual property to seek regulatory approvals, with the